JAZZ PHARMACEUTICALS PLC news, videos and press releases - Page 5
For more news please use our advanced search feature.
JAZZ PHARMACEUTICALS PLC - More news...
JAZZ PHARMACEUTICALS PLC - More news...
- Jazz Pharmaceuticals to Present Pan-RAF Inhibitor Pre-Clinical Data at American Association for Cancer Research (AACR) 2022 Annual Meeting
- JAZZ PHARMACEUTICALS ANNOUNCES FULL YEAR AND FOURTH QUARTER 2021 FINANCIAL RESULTS
- JAZZ PHARMACEUTICALS ANNOUNCES FULL YEAR AND FOURTH QUARTER 2021 FINANCIAL RESULTS
- Jazz Pharmaceuticals to Participate in Upcoming March Investor Conferences
- Jazz Pharmaceuticals to Report 2021 Fourth Quarter and Full Year Financial Results on March 1, 2022
- Jazz Pharmaceuticals to Report 2021 Fourth Quarter and Full Year Financial Results on March 1, 2022
- Jazz Pharmaceuticals Completes U.S. FDA Supplemental Biologics License Application for Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) Monday/Wednesday/Friday Dosing Schedule
- Jazz Pharmaceuticals Announces Vision 2025 to Deliver Sustainable Growth and Enhanced Value to Drive Transformation to Innovative, Global Biopharmaceutical Leader
- Jazz Pharmaceuticals Announces Vision 2025 to Deliver Sustainable Growth and Enhanced Value to Drive Transformation to Innovative, Global Biopharmaceutical Leader
- Lancet Neurology Publishes Positive, Pivotal Phase 3 Data of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Idiopathic Hypersomnia
- Jazz Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference
- U.S. FDA Grants Orphan Drug Exclusivity (ODE) for Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Idiopathic Hypersomnia in Adults
- Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Trial Evaluating JZP150 for Once-Daily Treatment of Adults with Post-Traumatic Stress Disorder
- Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2b Clinical Trial Evaluating Novel Suvecaltamide (JZP385) for Once-Daily Treatment of Adults with Essential Tremor
- Jazz Pharmaceuticals Presents Positive Interim Phase 2/3 Results of Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) in Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma at ASH 2021 Annual Meeting
- Jazz Pharmaceuticals to Present from Expanding Neuroscience Portfolio Epidiolex® (cannabidiol) Oral Solution Data at the 2021 American Epilepsy Society Annual Meeting
- Jazz Pharmaceuticals Announces First Patient Enrolled in IMforte Phase 3 Trial Evaluating Zepzelca® (lurbinectedin) in Combination with a PD-L1 Inhibitor in Small Cell Lung Cancer
- Jazz Pharmaceuticals to Participate in Upcoming November Investor Conferences
- Jazz Pharmaceuticals to Participate in Upcoming November Investor Conferences
- Jazz Pharmaceuticals Announces Third Quarter 2021 Financial Results And Raises Full Year Earnings Guidance
- Jazz Pharmaceuticals Announces Third Quarter 2021 Financial Results And Raises Full Year Earnings Guidance
- Jazz Pharmaceuticals to Present Data Showcasing Clinical Advances Across Hematology/Oncology at ASH 2021 Annual Meeting
- Jazz Pharmaceuticals to Present Data Showcasing Clinical Advances Across Hematology/Oncology at ASH 2021 Annual Meeting
- Jazz Pharmaceuticals to Report 2021 Third Quarter Financial Results on November 9, 2021
- Jazz Pharmaceuticals to Report 2021 Third Quarter Financial Results on November 9, 2021
- Jazz Pharmaceuticals Announces Xywav® (calcium, magnesium, potassium, and sodium oxybates) Investor Webcast on October 13, 2021
- Jazz Pharmaceuticals Announces Xywav® (calcium, magnesium, potassium, and sodium oxybates) Investor Webcast on October 13, 2021
- Jazz Pharmaceuticals to Participate in Upcoming September Investor Conferences
- Jazz Pharmaceuticals to Participate in Upcoming September Investor Conferences
- Jazz Pharmaceuticals Announces U.S. FDA Approval of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Idiopathic Hypersomnia in Adults